YM BioSciences Inc. (YMI)

[Harleyman]

News for 'YMI' - (YM BioSciences Reports CYT387 Phase I/II Results Selected for Oral Presentation at ASH2012 Conference)


MISSISSAUGA, ON, Oct. 11, 2012, 2012 (Canada NewsWire via COMTEX) -- YM
BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing
hematology and cancer related products, today announced that the results of its
Phase I/II Study of CYT387, a JAK1/JAK2 inhibitor currently being evaluated for
the treatment of myelofibrosis, have been selected by the ASH Program Committee
for presentation in an Oral Session at the 2012 Annual Meeting of the American
Society of Hematology to be held in Atlanta, Georgia on December 9, 2012.

"CYT387 could prove to be an important and differentiated therapeutic for
patients with myelofibrosis; the interim data we have reported to date have been
highly encouraging," said Dr. Nick Glover, President and CEO of YM BioSciences.
"We look forward to the release of final nine-month data from the Phase I/II
CYT387 study at ASH, as well as further ongoing data from the many patients who
continue to benefit from the drug in its Extension trial."

Title: Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of
Myelofibrosis Session Name: 634. Myeloproliferative Syndromes - Clinical:
Myeloproliferative Neoplasms - Novel Therapies I Session Date: Sunday, December
9, 2012; 4:30 PM - 6:00 PM (Presentation Time: 5:15 PM) Location: Georgia World
Congress Center, Room B213-B214

AboutYM BioSciences YM BioSciences Inc.is a drug development company primarily
focused on advancing CYT387, an orally administered inhibitor of both the JAK1
and JAK2 kinases, which have been implicated in a number of hematological and
immune cell disorders including myeloproliferative neoplasms and inflammatory
diseases as well as certain cancers. Positive interim results have been reported
from a Phase I/II trial of CYT387 in 166 patients with myelofibrosis. YM's
portfolio also includes nimotuzumab, a humanized monoclonal antibody targeting
EGFR with an enhanced side-effect profile over currently marketed EGFR-targeting
antibodies. Nimotuzumab is being evaluated in numerous Phase II and III trials
worldwide. In addition, YM has several preclinical programs underway with
candidates from its library of novel compounds identified through internal
research conducted at YM BioSciences Australia.

This press release may contain forward-looking statements, which reflect the
Company's current expectation regarding future events. These forward-looking
statements involve risks and uncertainties that may cause actual results, events
or developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include, but are not limited to, changing market conditions, the
successful and timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and pricing, new product
development, uncertainties related to the regulatory approval process or the
ability to obtain drug product in sufficient quantity or at standards acceptable
to health regulatory authorities to complete clinical trials or to meet
commercial demand; and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting. Certain of the assumptions made in
preparing forward-looking statements include but are not limited to the
following: that CYT387 and nimotuzumab will generate positive efficacy and
safety data in ongoing and future clinical trials, and that YM as well as
CIMYM's various licensees will complete their respective clinical trials and
disclose data within the timelines communicated in this release. Except as
required by applicable securities laws, we undertake no obligation to publicly
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

SOURCE: YM BioSciences Inc.

To view this news release in HTML formatting, please use the following URL:
http://www.newswire.ca/en/releases/archive/October2012/11/c6015.html

SOURCE: YM BioSciences Inc.